Consumer-referred health care (CDHC) after the end of „managedcare “in theUnited conditions during the end of the 90en years, which are latest new idea in the American public health policy, which is not called euphemistisch consumer-referred health care, into force the anything different than health insurance with the very high annual Deductibles is and extended, in the United States, from$2,000 per family to $10,000 or more. Straight ones looked for asAmerican management consultants, „handled care “around the ball during the nineties-years to marked out, therefore they are suitable, CDHC in early 21. Century as new American invention to marked out, although it is however a certain variant of the medical approach of the savings account (MSA), which is used long in Singapore. For whatever or against the CDHC approach can be said, can it is not supporting judged of research-created pharmaceutical industry, since patients are exposed to the full costs that use up-requiring medicines within the high Deductibles. It is special insurance precautions for use up-requiring medicines, on which plausible argument are met, which the lowering of its costs can help to the patients to avoid expensive hospitalizing and other more expensive acute care is suitable the approach, with the profit margins and the financing of R& to collide strictly; D in the industry. It is a development, which is to give the industrial break. Information infrastructure pharmaceutical market, if the market energy, which is associated in the decisions of the patients, in which controlling of the health care is to be effectively linked up costs, then it becomes substantial that patients, as well as its physicians are better informed, as it is now over the relative costs and the use of the rivaling products with the same therapeutic goal, briefly said, on its relative „profitability. “The development such an information lower surface is another main challenge of the public health policy manufacturers in the coming decades. The mechanism of the relative profitability of the rivaling pharmaceutical products raises extraordinary methodologische problems, as greatly well-being descriptive in the Bible for such studies, Drummond et al. Methods for the economic evaluation of the health care programs (2005). „The costs “, which are used in such evaluations, can be analyzed narrowly, in order to be only those the insurer or the insurer and the patients, or all social costs to cover including very far those of the family members, of the employers and of others in the society to be carried (e.g., infection). Use in the Kostengünstigkeitstudien is usually measured by physical Gesundheitstatus announcements, stored like added life years or changes in the blood pressure, but they must be adjusted to the quality of life, which release in sequence a landlord of the additional methodologischen challenges and, at information Infrastructure OF the Pharmaceutical Market If the market power inherent into the decisions OF patients is tons of fuel element more effectively harnessed into the control OF health care costs, then it becomes essential that patients, as wave as their physicians, acres more better informed than they now acres about the relative costs and benefits OF rival products with the same therapeutic target, in short, on their relative “cost effectiveness.” The development OF look for at information base wants fuel element another major challenge OF health policy makers into the coming decades. The establishment OF the relative cost effectiveness OF rival pharmaceutical products pos extraordinary methodological problem, as is superbly wave described into the bible for look for studies, Drummond et al. 's Methods for the Economic evaluation OF Health Care of program (2005). The “costs” used in look for evaluation CAN fuel element narrowly construed tons of fuel element only those OF insurers or OF insurers and patients, or very widely ton include all social costs, including those founts by family members, employers, and others in society (e.g., though contagion). Benefits into cost effectiveness studies typically acres measured by physical health status of indicator, look for as added life years saved or CHANGEs into blood pressure, but they must fuel element adjusted for the quality OF life, which and challenges in turn of trigger A host OF additional methodological,